Safety study of an investigational drug for advanced cancer with the CLDN6 marker
Part of Cancer, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (or 15 years or older if you are in the US).
- Your tumor must have a specific marker called CLDN6.
- You must have advanced cancer of the ovary, fallopian tube, lining of the abdomen, or endometrium, or a germ cell tumor.
- Your cancer must have gotten worse or not responded to standard treatments.
- If you have brain metastases, they must be treated and stable for at least a month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
This early-phase trial tests an investigational drug (AT03-65) for people with advanced solid tumors that have a certain protein called CLDN6. The goal is to see if the drug is safe and if it might help shrink tumors.
This study tests an experimental drug called QLS5132 for people with advanced solid tumors (cancers that start in organs or tissues). The drug targets a protein called CLDN6 on some cancer cells and might help stop the tumor from growing.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.